What Is the Treatment for Bleeding Behind the Eye?

Treatment for bleeding behind the eye ranges from simple observation to emergency surgery, and the right approach depends almost entirely on where the blood has collected, how much there is, and what caused it. “Bleeding behind the eye” is not a single condition. Blood can pool in the vitreous gel that fills the eyeball, beneath the retina, or in the bony orbit surrounding the eye, and each scenario calls for a different response. Some cases resolve on their own with no intervention. Others require an operating room within hours to prevent permanent blindness.

Why Location Matters So Much

The eye has several compartments, and blood in one compartment behaves very differently from blood in another. Vitreous hemorrhage, where blood leaks into the clear jelly inside the eye, is the most common form doctors see. It clouds vision like looking through a red or dark fog, but the retina underneath may be perfectly intact. Retrobulbar hemorrhage is blood trapped in the orbit behind the eyeball, which can compress the optic nerve and cut off its blood supply. Submacular hemorrhage is blood pooling directly beneath the macula, the part of the retina responsible for central vision, and it can cause rapid, severe damage to the light-sensing cells. Each of these has its own treatment ladder, and a doctor’s first job is figuring out exactly which type they are dealing with.

Diagnosis often involves ultrasound when the bleeding is dense enough to block direct visualization of the retina. B-scan ultrasonography has proven highly accurate for detecting problems like retinal detachment behind a curtain of blood, with one study reporting perfect sensitivity for finding retinal detachments and new retinal tears when a standardized protocol was used.¹ That matters because the treatment plan changes dramatically if the retina has detached versus if it is still in place.

Emergency Treatment for Retrobulbar Hemorrhage

Retrobulbar hemorrhage is the scenario that keeps emergency physicians up at night. When blood fills the small, enclosed space behind the eyeball, pressure builds fast. The eye bulges forward, the eyelids become tense and difficult to open, and the optic nerve can be strangled by the rising pressure within minutes to hours. Left untreated, this leads to permanent vision loss. Causes include blunt trauma to the face, complications from sinus surgery, and occasionally spontaneous bleeding in people on blood thinners.²

The frontline emergency treatment is a procedure called lateral canthotomy and cantholysis. A doctor makes a small cut at the outer corner of the eye and then snips the tendon holding the lower eyelid taut against the orbit. This releases enough space for the eyeball to move forward, immediately lowering the pressure on the optic nerve. It can be done at the bedside with local anesthesia and takes only a few minutes.³ The procedure is considered so time-sensitive that emergency physicians, not just ophthalmologists, are trained to perform it.⁴

In some cases, the initial canthotomy buys time but does not fully resolve the pressure. Case reports describe patients who required a follow-up procedure called orbital septum release under general anesthesia about an hour after the initial bedside cut, allowing wider decompression of the orbital tissues.⁵ The key message is that speed matters more than perfection here. Getting even partial decompression done quickly is far better than waiting for an operating room to open up.

Conservative Management of Vitreous Hemorrhage

Vitreous hemorrhage is more common and usually less urgent than retrobulbar bleeding. Blood leaks from damaged retinal blood vessels into the vitreous gel, and the most frequent culprits are diabetic retinopathy, retinal vein occlusion, and retinal tears. When the bleeding is not too dense and the retina appears intact on ultrasound, the standard first step is watchful waiting.

Initial management typically involves observation for about four to six weeks, giving the blood time to settle and the body a chance to reabsorb it naturally.⁶ During this period, you might expect your doctor to recommend sleeping with your head slightly elevated, the idea being that gravity helps the blood settle away from the center of your visual axis. Interestingly, research has challenged this long-standing advice. A study examining head elevation during conservative treatment of vitreous hemorrhage found that keeping the head elevated did not improve central clearance of blood and actually caused more discomfort and neck pain during sleep. Resting with a normal pillow worked just as well for vision improvement.⁷

During the observation period, patients are typically told to avoid strenuous activity and blood-thinning medications when possible. The doctor monitors whether the blood is clearing and uses ultrasound to watch for complications like retinal detachment. If the blood clears sufficiently, the underlying cause (such as abnormal blood vessels from diabetes) can then be treated directly.

When Surgery Becomes Necessary

When vitreous blood does not clear on its own after several weeks, the standard surgical intervention is pars plana vitrectomy. This involves inserting tiny instruments through small incisions in the white of the eye, removing the blood-filled vitreous gel, and replacing it with a clear saline solution or gas bubble. Modern vitrectomy uses instruments as small as 23 or 25 gauge, which are thin enough that the incisions often do not need stitches. Non-clearing vitreous hemorrhage is the most common reason vitrectomy is performed in patients with diabetic retinopathy.⁶

Beyond simply clearing the blood, vitrectomy gives the surgeon a clear view of the retina so they can repair any tears, remove scar tissue, and apply laser treatment in the same session. For diabetic vitreous hemorrhage specifically, the combination of vitrectomy with other treatments like laser and anti-VEGF injections has become the standard approach.⁸ Surgery is also moved up earlier when ultrasound reveals a retinal detachment hiding behind the blood, since a detached retina becomes harder to repair the longer it stays peeled away.

Anti-VEGF Injections and Laser Photocoagulation

Many cases of bleeding behind the eye are caused by abnormal new blood vessels that grow in response to poor oxygen supply in the retina. These fragile vessels bleed easily. Two treatments target this root cause: anti-VEGF injections and laser photocoagulation.

Anti-VEGF drugs (such as ranibizumab, bevacizumab, and aflibercept) block a protein that signals new blood vessel growth. They are injected directly into the eye, and while the idea of a needle in the eye sounds alarming, the procedure is brief and done with numbing drops. In diabetic retinopathy, anti-VEGF therapy has been shown to reduce both vitreous hemorrhage and the need for vitrectomy surgery compared to laser treatment alone.⁹ When vitrectomy is ultimately needed, giving an anti-VEGF injection a few days before surgery helps shrink the abnormal blood vessels, making the operation safer and reducing bleeding during the procedure.¹⁰

Laser photocoagulation takes a different approach. Rather than blocking blood vessel growth chemically, it uses focused light energy to seal leaking vessels or to destroy areas of oxygen-starved retina so they stop sending out the chemical signals that trigger abnormal vessel growth.¹¹ Panretinal photocoagulation, where hundreds of tiny laser burns are placed across the peripheral retina, has been a mainstay of treatment for proliferative diabetic retinopathy for decades. It works, but it sacrifices some peripheral and night vision in the process. This tradeoff is partly why anti-VEGF injections have gained ground as an alternative first-line treatment in many cases.

For conditions like central retinal vein occlusion, the evidence for preventive laser is more nuanced. One long-running study found that panretinal laser did reduce abnormal blood vessel growth on the iris when applied within three months of the blockage, but it did not produce a clear difference in overall visual outcomes or the rate of vitreous hemorrhage compared to no laser.¹² This is an area where treatment decisions depend heavily on the specific clinical picture.

Treating Blood Beneath the Retina

Submacular hemorrhage is a particularly damaging form of ocular bleeding. When blood collects directly under the macula, it is toxic to the photoreceptors. The iron in hemoglobin damages retinal cells within days, and a clot pressing against the macula blocks nutrients from reaching it. Left alone, the blood can cause permanent scarring and central vision loss. This creates real urgency to move the blood away from the macula as quickly as possible.

The most widely studied approach combines an injection of tissue plasminogen activator (tPA), a clot-dissolving drug, with a gas bubble. The tPA liquefies the clotted blood, and the gas bubble, positioned by having the patient keep their head face-down, physically pushes the dissolved blood away from the macula. In one of the earlier studies of this technique, blood was completely displaced from beneath the macula in about seven out of ten patients, and over half gained meaningful improvement in vision within two months.¹³

There are two ways to deliver the tPA: injecting it into the vitreous cavity (intravitreal) or delivering it directly under the retina during vitrectomy surgery (subretinal). Research comparing the two approaches in age-related macular degeneration has found them roughly equally effective at displacing the blood.¹⁴ The intravitreal approach is simpler and can be done outside the operating room, which is an advantage when time matters. The same technique has also been used successfully in younger patients, including a case involving a child with submacular bleeding caused by traumatic choroidal rupture.¹⁵

When the underlying cause is wet age-related macular degeneration, the tPA-and-gas procedure is often combined with an anti-VEGF injection at the same time. One study using this triple combination found that vision improved dramatically, with patients going from barely being able to count fingers to reading several lines on the eye chart, and the blood was successfully displaced in every patient treated.¹⁶ Still, the long-term outlook depends heavily on the health of the underlying retina. When macular degeneration is advanced, removing the blood may temporarily improve vision, but the disease itself limits how much recovery is possible.

How Timing Shapes the Outcome

Across nearly every type of ocular bleeding, treatment timing has a measurable impact on results. For retrobulbar hemorrhage, the window is measured in minutes to hours. For submacular hemorrhage, a study found that blood present for 14 days or less was associated with significantly better visual gains after treatment than older hemorrhages.¹⁷ The reason is straightforward: the longer blood sits against the retina, the more damage it does to the delicate photoreceptors, and no amount of surgical skill can repair cells that have already died.

Surgical removal of submacular blood has shown encouraging results when done promptly. In one surgical series, about four out of five patients had improved vision after the procedure, and nearly three-quarters achieved vision good enough to read large print.¹⁸ But gains were limited in eyes where the hemorrhage had been present for more than 30 days or where active abnormal blood vessels remained under the macula. A separate study reported that roughly half of treated patients saw improvement, with better outcomes in those whose underlying macular disease was less advanced.¹⁹

The practical takeaway is that sudden vision loss, a shower of new floaters, or a dark shadow spreading across your visual field should prompt same-day or next-day evaluation. Waiting a week “to see if it gets better” can cost irreplaceable retinal cells.

Treating Bleeding From Retinal Vein Occlusion

Retinal vein occlusion, where a clot blocks one of the retina’s drainage veins, is a common cause of bleeding inside the eye. The blocked vein raises pressure in the retinal capillaries, which then leak blood and fluid. Treatment targets both the immediate complications and the underlying vascular problem.

The available treatment options are wide-ranging and include anti-VEGF injections, laser therapy, intravitreal steroids, and occasionally vitrectomy.²⁰ Anti-VEGF injections have become the dominant first-line treatment for the macular swelling that accompanies vein occlusions, often requiring repeated injections over months to keep the swelling controlled.

Whether blood thinners help after a retinal vein occlusion has been studied extensively. A meta-analysis pooling data from dozens of studies found that about two-thirds of patients on anticoagulant therapy had improved vision compared to roughly a third of those on antiplatelet therapy. The recurrence rate of vein occlusion was also somewhat lower with anticoagulants. However, anticoagulant therapy carries its own risks: about one in 20 patients experienced major bleeding events.²¹ For patients already taking blood thinners for heart conditions or stroke prevention, managing the balance between preventing clots and avoiding bleeding complications in the eye requires careful coordination between the eye doctor and the prescribing physician.

Retinal Hemorrhages in Children

Bleeding behind the eye in infants and young children occupies a unique space in medicine because of its strong association with abusive head trauma, sometimes called shaken baby syndrome. While accidental injuries can occasionally cause retinal hemorrhages in children, the pattern and severity of the bleeding often help distinguish abuse from accident.

Research has found that the presence of retinal hemorrhage in a child being evaluated for possible abuse was strongly associated with a confirmed or probable abuse diagnosis, with the odds being particularly high in infants under six months old.²² The severity of the hemorrhages correlated with the likelihood of abuse, and the most severe presentations were found exclusively in abused children. Abusive head trauma tends to produce hemorrhages that extend from the center of the retina all the way to its edges and that affect multiple layers of the retina, including findings like splitting of the retinal layers (retinoschisis) and retinal folds, features thought to result from violent shaking forces transmitted through the vitreous gel.²³

Treatment in these cases focuses first on the child’s overall medical stabilization, since brain injuries from abusive head trauma are often life-threatening. The retinal hemorrhages themselves usually resolve over weeks as the blood is reabsorbed, though severe cases can leave lasting damage to the retina. An ophthalmologic examination with careful documentation, increasingly using wide-field photography, serves both a diagnostic and a medicolegal purpose.²⁴

The Risk of Scarring After Ocular Bleeding

Even when blood is successfully cleared from the eye, whether by the body’s own processes or by surgery, the aftermath can include scarring that limits visual recovery. Blood inside the eye triggers a wound-healing cascade, and in the retina this can lead to fibrosis, where scar tissue forms along the retinal surface or beneath it. In wet macular degeneration, the abnormal blood vessels that cause hemorrhaging also provoke fibrotic scarring, and this scar tissue is ultimately what destroys central vision in many patients.²⁵ In diabetic eye disease, similar proliferative scarring can pull on the retina and cause tractional retinal detachment, one of the most serious complications.

This is part of why treatment aims not just to remove the blood but to address whatever caused the bleeding in the first place. If diabetic retinopathy is the culprit, ongoing blood sugar control and regular anti-VEGF or laser treatment can prevent new hemorrhages. If wet macular degeneration is responsible, long-term anti-VEGF injections are the standard of care. Clearing the blood without managing the underlying disease is treating the symptom while ignoring the cause.

Gene Therapy on the Horizon

The biggest practical limitation of anti-VEGF treatment is that it requires repeated injections, often monthly or every other month, sometimes for years. Each visit means a trip to the ophthalmologist’s office, numbing drops, and a needle. Researchers are working on gene therapy approaches that could potentially deliver a one-time treatment, enabling the eye’s own cells to continuously produce anti-VEGF proteins on their own. Early-stage trials have used viral vectors to carry these genes into retinal cells, and animal studies with gene-editing tools have shown the ability to suppress abnormal blood vessel growth.²⁶ These approaches are still years from widespread clinical use, but they represent the most plausible path toward reducing the injection burden that patients with chronic retinal bleeding face.